Kornimate/medical-research-clean huggingface dataset:
biological bank for atrial fibrillation and stroke

Conditions: Stroke; Atrial Fibrillation

Summary: atrial fibrillation (af) is the most common cardiac arrhythmia encountered in clinical practice. this arrhythmia is responsible for 15% of strokes and more than 30% of strokes on people over 65 years. according to studies, 30 to 40% of isolated atrial fibrillations could be familial. atrial fibrillation has significant genetic heterogeneity. about 40 genes have been identified as potentially involved. studies have identified genes common to the risk of atrial fibrillation and stroke. despite the pathophysiology of atrial fibrillation has been intensively and extensively studied for almost a century, there are still many questions. the pathophysiology is not sufficiently understood to allow finding more effective therapies. it is necessary to identify genetic determinants and thus potentially new pharmacological targets more adapted. the establishment of a biological database will test hypotheses concerning the genetic origin and thromboembolic process of atrial fibrillation and associated stroke.


Eligibility criteria:
group 1a * inclusion criteria : - af history * exclusion criteria : * no af history * patient who didn't signed consent group 1b * inclusion criteria : * af history * scheduled electrophysiological exploration or af ablation * exclusion criteria : * no af history * pregnant women * patient who didn't signed consent group 1c * inclusion criteria : * af/at history * stroke history * exclusion criteria : * no stroke history * patient who didn't signed consent group 2 * inclusion criteria : * patient over 80 * ecg: sinusal rhythm * tte : no left atrial dilatation * exclusion criteria : * atrial fibrillation history * tte : left atria \>25cm², \> 34m/m2), fevg \< 50% * ecg : qrs \> 90 ms * cardiac pathologies (excepted hypertension and valvulopathies) * history of stroke and transient ischemic attack * patient who didn't signed consent group 3 * inclusion criteria : * cryptogenic stroke or transient ischemic attack history before 50 yo * no af history * exclusion criteria : * af history * stroke or transient ischemic attack over 50 yo * patient who didn't signed consent
efficacy of hyaluronic acid in prevention of acute radiation proctitis

Conditions: Acute Radiation Proctitis; Acute Radiation Enteritis

Summary: a randomized placebo-controlled clinical trial to evaluate efficacy of hyaluronic acid in prevention of acute radiation proctitis among oncology patient population especially who are diagnosed with abdomeno-pelvic tumors and subsequently required radiotherapy.


Eligibility criteria:
inclusion criteria: * all patients diagnosed with pelvic or gastrointestinal malignancies (tumors in uterus, cervix, prostate, seminal vesicles, kidney, colon, etc.), * all patients who required adjuvant or radical radiation therapy; * age \&lt; 80 years; * karnofsky performance status ≥ 60 exclusion criteria: * patients were excluded if they had * gt; previous pelvic radiotherapy, * gt; inflammatory bowel disease or * gt; rectal issues (e.g., haemorrhoids). * patients diagnosed with cancer rectum

Keywords: double blind placebo control randomized clinical trial
long-term, follow-up study of the safety and efficacy of levetiracetam in children with partial onset seizures

Conditions: Epilepsy, Partial

Summary: to allow pediatric patients with partial onset seizures an opportunity to receive (as follow-up to studies n01009(nct00105040)/n01103(nct00175890) or by direct enrollment) open-label levetiracetam treatment, continue studying cognition and behavior in children, and continue collection of safety/efficacy data.


Eligibility criteria:
inclusion criteria: * pediatric patients with partial onset seizures, with 1 to 2 anti-epileptic drugs (aeds), with participation in previous levetiracetam pediatric studies (n01009 or n01103) or direct enrollment, for whom levetiracetam treatment will be of possible benefit exclusion criteria: * patients on a ketogenic diet * seizures too close together to accurately count * pseudoseizures * status epilepticus 1 month prior visit 1 * current diagnosis of lennox-gastaut syndrome or epilepsy secondary to a progressing cerebral disease will be excluded from the study.

Keywords: partial onset seizures levetiracetam epilepsy keppra
safety and efficacy study using 5-ala oral administration as an adjuvant therapy on the rate of local tumor recurrence in patients who have desmoids tumors

Conditions: The Aim of the Study is to Evaluate the Efficacy of Photodynamic Therapy as an; Adjuvant Therapy on the Clinical Outcome of Patients With Desmoid Tumors After; Surgical Resection

Summary: the purpose of this study is to evaluate the efficacy of preoperative 5-ala oral administration and subsequently intraoperative tumor bed phototherapy with red light laser, as an adjuvant therapy on the 3 years rate of local tumor recurrence in patients with desmoid tumors. to evaluate the safety of 5-ala administration. 5 years local recurrence rate.


Eligibility criteria:
inclusion criteria: 1. patient has a resectable histologically confirmed desmoid tumor. 2. previously treated (by chemotherapy, irradiation or surgery) patients are eligible. 3. age \> 18 years 4. signed informed consent prior to patient recruitment. - exclusion criteria: 1. hepatic enzymes or bilirubin \> 2x upper limit of normal. 2. serum creatinine \> 2.5 x upper limit of normal. 3. suspected /documented metastatic disease. 4. active or uncontrolled infections. 5. active second malignant disease (excluding non-melanoma skin cancer, or in situ cervix or breast carcinoma) \< 2 years prior to the study. 6. use of other investigational agents \< 30 days prior to the study. 7. patients who are mentally or physically unable to comply with all aspects of the study. 8. any serious medical condition, including the presence of laboratory abnormalities, which places the subject at an unacceptable risk if he or she participates in this study or confounds the experimental ability to interpret data from the study. 9. pregnant or lactating females. 10. known intolerance or allergy to 5-ala 11. suspicious or documented acute or chronic porphyria
efficacy of conservative treatment of functional defecatory disorders in females with pelvic organ prolapse

Conditions: Pelvic Floor Prolapse; Functional Constipation; Rectocele

Summary: this study is planned to evaluate the efficacy of complex conservative treatment (including tibial neuromodulation, biofeedback therapy, special pelvic floor training and diet modification) in women with pelvic organ prolapse

pelvic organ prolapse is a condition with impaired anatomic structure, which may result in defecatory disorders and usually considered as an indication for surgery. however, operation is not always possible. existing data suggest that functional component may also be possible, despite on the anatomic impairment. the aim of the study is to evaluate the effect of complex conservative treatment of functional defecatory disorders in patients with mild to moderate grade of pelvic organ prolapse

Eligibility criteria:
inclusion criteria: * willingness to participate (signed informed consent form) * females with rectocele i-ii grade or rectocele i-ii grade and internal rectal invagination and functional defecatory disorders (per rome iv guidelines) confirmed on the basis of complex examination including high-resolution anorectal manometry exclusion criteria: * rectocele iii grade; * internal genitals prolapse; * history of abdominal or pelvic surgery that may impact bowel motility (excluding non-complicated appendectomy or laparoscopic cholecystectomy); * gynecological surgery that may influence sensory or reservoir function of rectum; * history of major cardiovascular events, or presence of current conditions that in case of participation of the patient in the study may put her at risk of exacerbation or complication; * start of any new concomitant medication with mechanisms of action that influence rectal motility, sensory function, muscle tone and/or contractility * inability to understand and/or follow the instructions to perform all the procedures required per protocol * general condition of the patient that make her ineligible by the discretion of the investigator

Keywords: pelvic floor prolapse conservative treatment functional disorders of defecation rectocele diet modification biofeedback therapy tibial neuromodulation
randomized trial of dha for retinitis pigmentosa patients receiving vitamin a

Conditions: Retinitis Pigmentosa

Summary: the purpose of this trial is to determine whether a nutritional supplement in addition to vitamin a will slow the course of retinitis pigmentosa.

retinitis pigmentosa (rp) is a group of inherited retinal degenerations with a worldwide prevalence of approximately 1 in 4,000. patients typically report night blindness and difficulty with midperipheral visual field in adolescence. as the condition progresses, they lose far peripheral visual field. most patients have reductions in central vision by age 50 to 80 years. based on electroretinograms (ergs), the course of the disease can be slowed on average among adults on 15,000 iu/day of vitamin a palmitate. while conducting the trial on the effects of vitamin a on rp, it became apparent that another substance in the diet could be affecting the course of the disease. this prompted the present randomized, controlled trial. this study is a randomized, controlled, double-masked trial with a planned duration of 5 years. patients with the common forms of rp are assigned to either a test or a control group. all receive 15,000 iu/day of vitamin a palmitate in addition to either 1200 mg/d of docosahexaenoic acid or control capsules. participants will not know the contents of the supplement or the group to which they have been assigned until the end of the trial. the main outcome measurement is the total point score on the humphrey field analyzer (hfa). in addition, computer-averaged 30-hz cone erg amplitudes and visual acuity are measured annually.

Eligibility criteria:
inclusion criteria: ocular criteria: retinitis pigmentosa, typical (non-syndromic) forms best corrected visual acuity greater than or equal to (ge )20/100 hfa 30-2 total point score ge 250 db (decibels) 30 (hertz) hz erg cone amplitude ge 0.68 microvolts dietary criteria: dark fish intake less than or equal to (le) five servings per week dietary omega-3 fatty acid intake le 0.41 g/d preformed vitamin a intake in diet and supplements le 10,000 iu/d supplement intake le 5000 iu/d of vitamin a and le 30 iu/d vitamin e consumption le 3 alcoholic beverages per day medical and other criteria: body mass index less than (lt )40 and weight ge 5th percentile for age, sex, and height serum retinol level le 100 mg/dl and serum retinyl ester levels le 380 nm/l serum cholesterol level lt 300 mg/dl and serum triglyceride levels lt 400 mg/dl agree not to know study capsule content exclusion criteria: ocular criteria: no confounding ocular disease dietary criteria: no intake of cod liver oil or omega-3 capsules medical and other criteria: not pregnant or planning to become pregnant no clinically significant abnormal result on complete blood count or serum liver function profile no other disease which might affect absorption or metabolism of dha or vitamin a
nushield in surgical peroneal tendon repair

Conditions: Tendon Injuries; Tendinopathy

Summary: the purpose of this study is to evaluate the use of nushield in subjects requiring surgical tendon repair.

the objective of this clinical trial is to evaluate both the safety and efficacy of using the nushield® allograft in addition to standard of care surgical procedures in subjects requiring surgical repair of the peroneal tendon. the effects of this treatment will be assessed using: * questionnaires * visual analog scale foot and ankle (vas fa) * faam sport * promis global health sf * tegner activity scale * foot and ankle outcomes instrument (q1, q2) * swelling assessments * ultrasound imaging for tendon thickness, gliding and adhesion formation

Eligibility criteria:
inclusion criteria: * ages 18 to 60 inclusive * if female, actively practicing a medically relevant method of contraception, abstinent, surgically sterile, or post-menopausal (defined as no menses for at least 12 months) * have a diagnosis of one of the following in relation to the peroneal tendon: * tendonitis with mri confirmation * synovial inflammation * tear * diagnosis resulting from acute injury to the tendon exclusion criteria: * bmi equal to or greater than 35 * prior injury to the peroneal tendon * collagen disorders * inflammatory arteriopathies * immune compromised * diabetic * less than 6 months between injury and proposed surgery date * steroid injection within the past 6 weeks localized to the treatment area * pregnant within the past six (6) months, breast feeding and/or desire to become pregnant during the course of the study, as verified by urine pregnancy test within one week prior to treatment * history of more than two (2) weeks treatment with immuno-suppressants, including systemic corticosteroids or cytotoxic chemotherapy within one month prior to initial screening, or have received such medications during the screening period, or are anticipated to require such medications during the course of the study * taking any investigational drug(s) or therapeutic device(s) within 30 days preceding screening * history of radiation therapy of the affected foot * known history of having acquired immunodeficiency syndrome (aids) or hiv * currently involved in medical litigation, including worker's compensation claims of any type * unable to understand the objectives of the trial * presence of any condition(s) which, in the opinion of the investigator, would compromise the subject's ability to complete this study * having a known history of poor adherence with medical treatment * express an unwillingness to receive human allograft tissue

Keywords: tendon surgery nushield
epidemiological study on the management of out-of-hospital cardiac arrest survivors in champagne ardennes

Conditions: Out-of-hospital Cardiac Arrest

Summary: out-of-hospital cardiac arrest (ohca) is a public health problem, affecting 50,000 people per year in france. intervention time (initiation of cardiopulmonary resuscitation (cpr) and advanced cpr) are associated with a better prognosis. despite this, the latest published data show a very low overall survival (5%). our territory has only three centers distributed hospitals with both a 24-hour coronary angiography platform and an intensive care unit. finally, although 60% of acehs receive coronary angiography in the île de france region, it is performed on only 15% of patients in the reims university hospital. therefore, it seems essential to conduct a study on the reality of the support of aceh and to study the clinical and biological factors as well as the influence of the geographical distribution of specialized technical platforms on the prognosis of patients.


Eligibility criteria:
inclusion criteria: * patient victim of aceh in the champagne-ardenne region admitted living in hospital. exclusion criteria: * patient under the age of 18
role of propofol postconditioning on oxidative stress and cognitive function

Conditions: Cerebral Arterial Aneurysm

Summary: the purpose of this study was to evaluate differences between propofol postconditioning and sevoflurane anesthesia in the intracranial aneurysm surgery about antioxidant effect.

intracranial aneurysm surgery may lead to regional ischemic reperfusion injury. propofol, as an antioxidative phenol, has been demonstrated that mitigate the brain i/r in rats. as for sevoflurane, some investigation indicated that sevoflurane is able to reduce oxidative stress in cell(except neuronal cell lines ) and rodent models, but the antioxidant effect did not found in human minor incision surgeries, furthermore, oxidative stress was raised in the major surgeries including orthopedic surgeries, hysterectomy, cholecystectomy, and thoracotomy

Eligibility criteria:
inclusion criteria: * clinical diagnosis intracranial aneurysm surgery , * american society of anesthesiologists (asa)ⅰ-ⅱ. exclusion criteria: * severe hepatic and renal dysfunction * coagulation disorder * taking antioxidant perioperative period
recombinant covid-19 vaccine (cho cell, nvsi-06-09) phase iii clinical trial

Conditions: COVID-19; Coronavirus Infections

Summary: this clinical trial adopts a randomized, double-blind and placebo-controlled design. a total of 16000 participants are planned to be enrolled, of which, cohort 1: 15000 participants vaccinated with ≥2 doses of inactivated covid-19 vaccine for ≥6 months will be randomly administered at ratio of 1:1:1 with 1 dose of libp-rec-vaccine, bibp-rec-vaccine or placebo intramuscularly to the deltoid muscle of upper arm. cohort 2: 1000 participants vaccinated with ≥2 doses of mrna covid-19 vaccine for ≥6 months will be randomly administered at ratio of 1:1 with 1 dose of libp-rec-vaccine or bibp-rec-vaccine intramuscularly to the deltoid muscle of upper arm.


Eligibility criteria:
inclusion criteria: * age range: healthy population aged ≥18; * judged by the investigator that the health condition is well after inquiry and physical examination; * cohort 1: participants vaccinated with ≥2 doses of inactivated covid-19 vaccines for ≥6 months since the last dose of vaccination; cohort 2: participants vaccinated with ≥2 doses of mrna covid-19 vaccines for ≥6 months since the last dose of vaccination; * be able and willing to complete all prescribed study schedules during the whole study period; * the participant himself/herself is able and willing to understand study procedures, sign the informed consent form voluntarily after informed consent and comply to requirements of the study protocol. exclusion criteria: * symptomatic and suspected covid 19 infection positive ; * urine pregnancy test is positive; women of childbearing age who have positive urine pregnancy test, who are pregnant, lactating, or women who have planned pregnancy within 6 months; * auxiliary temperature before vaccination is ≥37.3℃ (tympanic/forehead temperature ≥37.8℃); * previous allergy history of vaccine vaccination (such as acute allergic reaction, urticaria, skin eczema, dyspnea, angioneurotic edema or abdominal pain, etc.) or allergy to known components of covid-19 vaccine; * have a history of hospital-diagnosed thrombocytopenia or other coagulation disorders; * with known immunological impairment or compromised immunological function diagnosed by the hospital; * received whole blood, plasma and immunoglobulin therapy within 1 month; * known or suspected of suffering from the following diseases: acute or chronic active respiratory diseases, severe cardiovascular diseases \[cardiopulmonary failure, hypertension uncontrollable by drugs (systolic blood pressure ≥ 150 mmhg and/or diastolic blood pressure ≥ 95 mmhg)\], acute infection, active phase of chronic disease, liver and kidney diseases, severe diabetes, malignant tumor, infectious skin diseases or severe skin allergy, hiv infection, etc. (examination report can be provided) * received live attenuated vaccine within one month before vaccination; * received inactivated vaccine within 14 days before vaccination; * other contraindications related to vaccination that investigators believe.

Keywords: covid-19
clinical trial for non-responders who previously participated in eltrombopag studies tpl 103922 or tpl 108390

Conditions: Hepatitis C

Summary: the purpose of this study is to test the safety and tolerability of eltrombopag when used to increase and maintain platelet count. platelet count to be maintained at a level sufficient to facilitate initiation of antiviral therapy, to minimize antiviral therapy dose reductions, and to avoid permanent discontinuation of antiviral therapy.


Eligibility criteria:
inclusion criteria: * prior participation in protocol tpl103922 or tpl108390 and completed the week 24 follow up visit in tpl103922 or tpl108390 * male or female ≥18 years old * evidence of chronic hcv infection * while participating in tpl103922 or tpl108390, discontinued from study drug due to thrombocytopenia * appropriate candidate for antiviral therapy with pegylated interferon plus ribavirin * platelet count \<75,000 * fertile males and females must use two forms of effective contraception during treatment and for 24 weeks after treatment * ability to understand and comply with the protocol requirements and instructions * ability to provide written informed consent exclusion criteria: * decompensated liver disease * known hypersensitivity, intolerance, or allergy to interferon, ribavirin, eltrombopag, or their ingredients * history of clinically significant bleeding from oesophageal or gastric varices * history of arterial or venous thrombosis and two or more of the following risk factors: hereditary thrombophilic disorders; hormone replacement therapy; systemic contraception (containing estrogen); smoking; diabetes; hypercholesterolemia; medication for hypertension or cancer * pre-existing cardiac disease (congestive heart failure grade iii/iv) or arrhythmias known to involve the risk of thromboembolic events (e.g. atrial fibrillation) * evidence of hepatocellular carcinoma * hiv or hepatitis b infection * therapy with anti-neoplastic or immunomodulatory treatment within six months prior to eltrombopag therapy * malignancy diagnosed or treated within the past five years. except for localized basal or squamous cell carcinoma treated by local excision or malignancies that were adequately treated and, in the opinion of the oncologist, have an excellent chance of cancer-free survival. * pregnant or nursing women * men with a female partner who is pregnant * history of alcohol/drug abuse or dependence within six months of the study start unless participating in a controlled rehabilitation programme. * treatment with an investigational drug or interferon within 30 days or 5 half-lives (whichever is longer) of the screening visit * history or platelet clumping that prevents reliable measurement of platelet counts * evidence of portal vein thrombosis within three months of baseline visit

Keywords: peginterferon platelets ribavirin hepatitis c-related thrombocytopenia thrombocytopenia hepatitis c thrombopoietin